BILL ANALYSIS

Senate Research Center

S.C.R. 34
By: Moncrief
Health & Human Services
3-19-97
As Filed

DIGEST

Currently, the federal Food and Drug Administration is charged with the approval process for new drugs. The approval process for new drugs, biological products, and medical devices is slower than the pace of scientific and medical advances. This proposal considers measures that would further improve the FDA's performance in approving new medical processes.

PURPOSE

As proposed, S.C.R. 34 submits the following resolutions:

> To urge the Congress of the United States to address this important issue by enacting comprehensive legislation to facilitate the rapid review and approval of innovative new drugs, biological products, and medical devices, without compromising patient safety or product effectiveness, and
>
> To provide that copies of this resolution be prepared and forwarded by the Texas secretary of state to the President of the United States, the Speaker of the United States House of Representatives, the President of the United States Senate, and to all members of the Texas delegation to the Congress with the request that this resolution be entered in the Congressional Record as a memorial to the Congress of the United States.